Eisler Capital UK Ltd. Makes New Investment in Exact Sciences Co. (NASDAQ:EXAS)

Eisler Capital UK Ltd. bought a new stake in Exact Sciences Co. (NASDAQ:EXASFree Report) in the fourth quarter, HoldingsChannel reports. The fund bought 7,196 shares of the medical research company’s stock, valued at approximately $532,000.

Several other large investors also recently modified their holdings of the business. AQR Capital Management LLC grew its position in shares of Exact Sciences by 172.0% in the 3rd quarter. AQR Capital Management LLC now owns 328,317 shares of the medical research company’s stock valued at $22,398,000 after purchasing an additional 207,623 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Exact Sciences by 1.6% in the third quarter. Nordea Investment Management AB now owns 18,858 shares of the medical research company’s stock valued at $1,310,000 after buying an additional 293 shares during the period. New York Life Investment Management LLC increased its position in shares of Exact Sciences by 5.0% during the fourth quarter. New York Life Investment Management LLC now owns 21,106 shares of the medical research company’s stock worth $1,561,000 after acquiring an additional 1,014 shares in the last quarter. Artisan Partners Limited Partnership raised its holdings in shares of Exact Sciences by 11.8% during the third quarter. Artisan Partners Limited Partnership now owns 3,961,514 shares of the medical research company’s stock worth $270,254,000 after acquiring an additional 418,770 shares during the period. Finally, Aviva PLC lifted its position in Exact Sciences by 383.0% in the 3rd quarter. Aviva PLC now owns 107,054 shares of the medical research company’s stock valued at $7,303,000 after acquiring an additional 84,888 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. BTIG Research lowered their target price on Exact Sciences from $85.00 to $80.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Jefferies Financial Group assumed coverage on Exact Sciences in a research report on Monday. They issued a “buy” rating and a $75.00 target price on the stock. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Canaccord Genuity Group lowered their price objective on shares of Exact Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Finally, TheStreet lowered shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.07.

View Our Latest Stock Analysis on Exact Sciences

Insiders Place Their Bets

In other news, EVP Sarah Condella sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the completion of the sale, the executive vice president now owns 71,787 shares of the company’s stock, valued at $5,025,090. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the transaction, the chief executive officer now owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Sarah Condella sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the sale, the executive vice president now owns 71,787 shares of the company’s stock, valued at $5,025,090. The disclosure for this sale can be found here. Insiders have sold 5,498 shares of company stock worth $370,105 in the last 90 days. Company insiders own 1.36% of the company’s stock.

Exact Sciences Trading Up 4.8 %

Shares of NASDAQ:EXAS opened at $45.55 on Thursday. The company has a 50-day simple moving average of $59.80 and a 200 day simple moving average of $63.02. The company has a market capitalization of $8.41 billion, a P/E ratio of -34.51 and a beta of 1.26. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.45 and a current ratio of 1.64. Exact Sciences Co. has a 52-week low of $43.30 and a 52-week high of $100.77.

Exact Sciences (NASDAQ:EXASGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). The business had revenue of $637.52 million for the quarter, compared to analyst estimates of $624.95 million. Exact Sciences had a negative net margin of 9.48% and a negative return on equity of 7.12%. Sell-side analysts forecast that Exact Sciences Co. will post -1.15 earnings per share for the current year.

About Exact Sciences

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Read More

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.